ADRX 0405
Alternative Names: ADRX-0405Latest Information Update: 10 Jul 2025
At a glance
- Originator Adcentrx Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Jul 2025 ADRX 0405 receives Orphan Drug status for Gastric cancer in USA
- 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 29 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Hormone refratory) in USA (Parenteral) (NCT06710379)